Clinical utility of KAP-1 expression in thyroid lesions.

Abstract

Although there are evidences of the involvement of KAP-1 in other tumors, data on differentiated thyroid carcinomas (DTC) are still lacking. We aimed to evaluate KAP-1 clinical utility in the diagnosis and prognosis of DTC. We used both visual immunohistochemistry and a semiquantitative analysis to evaluate KAP-1 expression in 230 thyroid carcinomas and 131 noncancerous thyroid nodules. There were 43 follicular carcinomas (FC) and 187 papillary thyroid carcinomas (PTC), including 130 classic (CPTC), 4 tall cells (TCPTC), and 53 follicular variants (FVPTC). Patients were followed up for 53.8 ± 41 months. They were classified as free-of-disease (142 cases) or poor outcome (25 cases--10 deaths), according to their serum Tg levels and image evidences. KAP-1 was identified in 78 % PTC, 75 % TCPTC, 74 % FC, 72 % FVPTC, 55 % FA, 44 % hyperplasia, and 11 % normal thyroid tissues. A ROC analysis identified malignant nodules with 69 % sensitivity and 75 % specificity, using a cutoff of 73.19. In addition to distinguishing benign from malignant thyroid tissues (p < 0.0001), KAP-1 expression differentiated CPTC from nodular hyperplasia (p < 0.0001), CPTC from FA (p = 0.0028), FVPTC from hyperplasia (p = 0.0039), and FC from hyperplasia (p = 0.0025). Furthermore, KAP-1 was more expressed in larger tumors (>4 cm; p = 0.0038) and in individuals who presented recurrences/metastases (p = 0.0130). We suggest that KAP-1 may help diagnose thyroid nodules, characterize follicular-patterned thyroid lesions, and identify individuals with poor prognosis.

• Authors: Mariana Bonjiorno Martins, Marjory Alana Marcello, Elaine Cristina Morari, Lucas Leite Cunha, Fernando Augusto Soares, José Vassallo, Laura Sterian Ward
• Journal: Endocrine pathology (Endocr Pathol) Vol. 24 Issue 2 Pg. 77-82 (Jun 2013) ISSN: 1559-0097 [Electronic] United States
• PMID: 23645532 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• Repressor Proteins
• TRIM28 protein, human
• Tripartite Motif-Containing Protein 28

Topics

• Adenocarcinoma, Papillary (metabolism, mortality, pathology)
• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Biomarkers, Tumor (metabolism)
• Carcinoma, Papillary, Follicular (metabolism, mortality, pathology)
• Female
• Humans
• Hyperplasia
• Male
• Middle Aged
• Prognosis
• Repressor Proteins (metabolism)
• Survival Rate
• Thyroid Gland (metabolism, pathology)
• Thyroid Neoplasms (metabolism, mortality, pathology)
• Thyroid Nodule (metabolism, mortality, pathology)
• Tripartite Motif-Containing Protein 28
• Young Adult